The delivery of synthetic poly (β-amino ester) combined with 5-FU and tiRNA-Gly-GCC inhibitors effectively suppresses tumor growth, enhances CRC sensitivity to 5-FU, and shows no significant adverse reactions in subcutaneous tumors, potentially providing a promising nanotherapy strategy for treating 5-FU resistant CRC (20). The gene discussed is GUCY2C; the disease is colorectal carcinoma.